& ldquo; Why do Chinese people see expensive medical treatment，The reason lies in 95%of my country's patented medicine、95%of medical equipment is monopolized by foreign companies。& rdquo; Qin Huaijin, Director of the Department of Science and Education and Education of the National Health and Family Planning Commission, frankly admitted at a meeting a few days ago。

 

  surey，This is exactly the embarrassing situation in the Chinese pharmaceutical industry，Surrounded by heavy soldiers by foreign pharmaceutical companies，How to highlight the siege，Tear open a mouth，Chinese new medicine research and development practitioners have been pursuing。

 

   & ldquo; Major special special & rdquo;

 

  Well -known，The development of the new drugs is & ldquo;、High risk、Long cycle。Usually，The average R & D of a new drug takes about 10 years，Spend at least $ 1 billion。But innovative drug research and development ability is a concentrated manifestation of a country's comprehensive strength in the field of life sciences。To achieve breakout，& ldquo; Twelve five & rdquo;，At & ldquo; Major new drug creation & rdquo; Under the support of major technology，China's pharmaceutical industry has realized the leap from imitation to innovation，Drug research and development capabilities have increased significantly，Ekidinib (Camina)、Imarinib、Apatinib、Sidamamine & Hellip; & Hellip; A series of innovative medicines are born，Bring the gospel to the patient。

 

  2011，Caimina developed by Beida Pharmaceutical，Used to treat advanced non -small cell lung cancer，Known as & ldquo; Domestic My stake betting appstake online sports bettingYiresha & RDQUO;。Since then，China becomes Ji Mei、British third country with completely independent intellectual property rights targeting anticancer drugs，Break the targeted therapy of lung cancer in one fell swoop for a long time to be monopolized by imported drugs。

 

  President of Zhejiang Beida Pharmaceutical Co., Ltd.、Chief scientist Wang Yinxiang said，For advanced lung cancer patients，This not only means that you can say goodbye to the traditional chemotherapy method，It can also increase the 5 -year survival period after chemotherapy from 6%& mdash; 10%to more than 20%，and the price is much lower than the import medicine。

 

  2014，Sidamamine will detonate the anti -cancer drug market when it is launched。Ning Zhiqiang, Executive Vice President of Shenzhen Micro Capital Biotechnology Co., Ltd., which develops Sidamamine, introduced and developed.。Sidamonamine currently approved for listing is the outer weekly T cell lymphoma (PTCL)，It is China's first approval treatment recurrence or difficulty cure PTCL drug。Preliminary clinical trial results show，Patient's clinical benefit rate is nearly 50%，A significant extension of the survival period。

 

  Since its listing，More than 1,000 patients in China have received Sidamonamine Treatment，Nearly half of patients with medication have appeared objective relief (that is, the tumor is clearly reduced)，Add this part of the patient to control the progress of the disease，The clinical benefit rate can reach 2/3。 & ldquo; It is worth mentioning that it is，The maximum treatment cost of similar drugs abroad is 280,000 yuan per month，Sidamamine only costs more than 20,000 per month，Is the price 1/10。At the same time，The charity assistance project of Sidamonamine is also conducted in an orderly manner。So far，Nearly 500 patients have benefited from assistance items，Get a lot of social benefits。& rdquo; Ning Zhiqiang said。

 

  Not only that，Innovative drugs developed by micro -core biology Steg Lie Sodium，The most fundamental mechanism for the occurrence and development of type 2 diabetes & mdash; & mdash; insulin resistance，belonging to the new generation of insulin allergenic drugs，At present, two Phase III clinical trials have been completed in China，There are nearly 1300 people in total cases。

 

   & ldquo; This is the largest in the history of the original new drug in China、Phase III clinical study in line with international test design and operation。If Siger Lie his sodium stake online sports bettingstake betting appdevelopment is successful，It will be a major contribution of the original new drug in China to diabetes and even the world。& rdquo; Ning Zhiqiang said。

 

  There are many examples like this，Since the implementation of major special projects，There are 90 varieties to get new drug certificates，135 varieties get clinical approval，18 international or international advanced category 1 new drugs were approved，International competitiveness has increased significantly。

 

  but，Zhang Xiquan, vice president of Zhengda Tianqing Pharmaceutical Group Co., Ltd.，It also has a unique advantage in doing innovative drugs in China，The labor cost of R & D is far lower than that of developed countries。At the same time，China's population is many，Patients with enrolled groups are huge，Low clinical trial cost，and the advantage of the post -issues obvious。

 

  Pharmaceutical companies call on policy support for innovative medicines

 

  & ldquo; National encouragement innovation，Innovative drugs require policy support。& rdquo; Wang Yinxiang said，Innovative drugs are in the process of entering the market，Facing obstacles，Among them, it is difficult for the medical insurance to be the first。

 

  Introduction to Wang Yinxiang，The current medical insurance reimbursement directory of the current drug was formulated and promulgated in 2009，It has been 7 years so far，New drugs developed and listed during this period have no chance to enter the reimbursement directory。

 

   & ldquo; The medical insurance directory has not been re -adjusted so far，and I don't know when it will be adjusted，So the new drugs listed during this time have no chance to compete for medical insurance directory。After our medicine enters the medical insurance directory，Revenue is 2 & mdash; 3 times higher than before entering the medical insurance，Can't enter the medical insurance directory，It has a great impact on the innovation enthusiasm of pharmaceutical companies。& rdquo; Wang Yinxiang said。

 

  surey，Ning Zhiqiang also called for，The government should treat domestic innovative enterprises more fairly in medical insurance policies，Take Sidamamamine as an example，No similar products in China，The pricing is not high，But except in April this year, it was included in Shenzhen local supplementary medical insurance drug directory，Time to enter national medical insurance，Still far away。

 

  Then is the tender mechanism。Wang Yinxiang said，Current，All drugs may not enter the hospital for sales without bidding，In addition to provincial bidding，The city and hospital My stake betting appMy stake betting appconsortium will also have a second bargain on the basis of bidding，For this，Enterprises will spend a lot of manpower、material resources。

 

   & ldquo; In addition，China needs to further improve the capital market in the future。Formulate different access policies according to the characteristics of enterprises in different industries，Give the wind investment funds with a more convenient exit channel，Only in this way can we encourage more funds to enter the field of innovative drugs with high risks but also have high returns。& rdquo; Ning Zhiqiang said。

 

  ■ Links

 

  The Road to the R & D of Sidam Benn

 

  Do new medicine，Life medicine that people can afford to be used by ordinary people，This is a dream in Ning Zhiqiang's heart。Now，As the Executive Vice President of Shenzhen Micro Capital Biotechnology Co., Ltd.，Ning Zhiqiang has already dreamed of real。December 23, 2014，Sidamamamine (Erotida) & mdash; & mdash; subtype selective group protein dehuminase oral inhibitors，Become the first oral medicine in the world for the treatment of malignant lymphoma，It is the first original innovative medicine in my country to authorize the patent of developed countries such as the United States，This day Ning Zhiqiang can be described as unforgettable for life。

 

  Recall 2001，When the micro -core creature was just established，There is no environment for innovative drugs at all，Hundreds of new drug research and development institutions，Including colleges and universities，The main focus is on the generic drug。& ldquo;，The new drug & rsquo;，More than 99%of them are generic drugs or Chinese medicine，Systemic mechanisms that have not yet formed innovative drug review and technical communication。& rdquo; Ning Zhiqiang said。

 

  As the first person to eat crabs，Qian has also become a big mountain in front of Ning Zhiqiang and their entrepreneurial teams。

 

   & ldquo; The biggest difficulty in returning to start a business is not technology，but the funds are stretched。& rdquo; Ning Zhiqiang said，2001，Micro -core creatures received the first 50 million yuan venture capital，But for the development of original new drugs，It is undoubtedly a glass of water。2003，Due to financing difficulties，The founder of the company、President Lu Xianping led other founders of other companies，Actively proposed to the board of directors to greatly reduce your salary。

 

   & ldquo; In order to make hematopoietic，2006，By authorized American companies to use our patent，At the same time，The core stake online sports bettingstake sports betting apptechnology platform is served as a multinational pharmaceutical company，Help us spend difficulties，Successful obtained the second round of financing。& rdquo; Ning Zhiqiang said。So far，Micro -core creatures have applied for 73 compound global invention patents，45 of which have been authorized; more than 30 papers are published in high -level academic journals at home and abroad。

 

  Like Ning Zhiqiang，Although 13 years have passed，President of Zhejiang Beida Pharmaceutical Co., Ltd.、Chief scientist Wang Yinxiang still remembers the difficulties of the beginning of the business。& ldquo;，R & D Center rented in a laboratory of more than 30 square meters，Several people share a computer。& rdquo;

 

  & ldquo; Although the conditions are not good，But our job is meticulous，Each link is high standard、Strict requirements。& rdquo; Wang Yinxiang said，That's it，Through the Tumor Institute of the Chinese Academy of Medical Sciences、The cooperation of domestic top -level research institutes such as the Drug Institute and the Shanghai Academy of Sciences，At the end of October 2005，According to pre -clinical research specifications (GLP)，Finally completed the company's first innovative medicine Camina's clinical development work。